compounding semaglutide news fda BreezeMeds Reviewed: 2026 Consumer Report on Breeze Meds GLP-1 Telehealth fda semaglutide compounding news New

It targets GLP-1 and GIP receptors to help reduce appetite and support weight loss, with dosing increased in clear steps under clinical supervision

Where DPC tends to be enough: You want faster access to a doctor when something feels off You need help starting or adjusting medication You want regular check-ins without worrying about copays You are trying to figure out whether therapy is needed Where it usually falls short: You already know you need weekly therapy You are dealing with trauma, grief, or long-term counseling needs You need specialist psychiatry You want structured mental health treatment beyond primary care If you are looking at options right now, it helps to look at how those pieces fit together before making a switch

By altering the amino acid in the peptide chain they resist degradation by the DPP4 enzyme

I'm Emily Kwong